Patient characteristics
| Parameter n (%)/median [range] . | Overall (n = 113) . | Decitabine (N = 73) . | Azacitidine (N = 40) . |
|---|---|---|---|
| Age, years | 70 [44-88] | 70 [44-88] | 70 [53-84] |
| WHO diagnosis | |||
| RCUD | 15 (13) | 10 (14) | 5 (13) |
| RCMD | 40 (35) | 29 (40) | 11 (28) |
| MDS with ringed sideroblasts | 3 (3) | 2 (3) | 1 (3) |
| MDS-EB | 25 (22) | 14 (19) | 11 (28) |
| 5q- | 2 (2) | 0 | 2 (5) |
| MDS-U | 6 (5) | 6 (8) | 0 |
| MDS/MPN-U | 6 (5) | 2 (3) | 4 (10) |
| CMML | 16 (14) | 10 (14) | 6 (15) |
| Therapy-related MDS | 20 (18) | 13 (18) | 7 (18) |
| ≥2 cytopenias | 68 (50) | 34 (47) | 22 (55) |
| Transfusion dependence | 59 (52) | 39 (53) | 20 (50) |
| BM blasts percentage | 3 [0-10] | 2 [0-10] | 3 [0-10] |
| Blasts ≥5% | 32 (28) | 21 (29) | 11 (27) |
| Cytogenetic risk (IPSS) | |||
| Good | 69 (61) | 43 (63) | 26 (65) |
| Intermediate | 30 (27) | 17 (23) | 13 (33) |
| Poor | 11 (10) | 10 (14) | 1 (3) |
| IPSS risk group | |||
| Low | 22 (19) | 16 (22) | 6 (15) |
| Intermediate-1 | 91 (81) | 57 (78) | 34 (85) |
| IPSS-R risk group | |||
| Very low | 14 (12) | 10 (14) | 4 (10) |
| Low | 41 (36) | 25 (34) | 16 (40) |
| Intermediate | 34 (30) | 21 (29) | 13 (33) |
| High | 23 (20) | 16 (22) | 7 (18) |
| Very high | 1 (1) | 1 (1) | 0 |
| MDACC LR-MDS score | |||
| Low | 13 (11) | 10 (14) | 3 (8) |
| Intermediate | 52 (46) | 35 (48) | 14 (43) |
| High | 48 (42) | 28 (38) | 20 (40) |
| Prior therapy | |||
| Growth factors | 22 (19) | 12 (16) | 10 (25) |
| Others | 9 (8) | 5 (7) | 4 (10) |
| Time from diagnosis, weeks | 5 [1-271] | 6 [1-216] | 4 [1-271] |
| Parameter n (%)/median [range] . | Overall (n = 113) . | Decitabine (N = 73) . | Azacitidine (N = 40) . |
|---|---|---|---|
| Age, years | 70 [44-88] | 70 [44-88] | 70 [53-84] |
| WHO diagnosis | |||
| RCUD | 15 (13) | 10 (14) | 5 (13) |
| RCMD | 40 (35) | 29 (40) | 11 (28) |
| MDS with ringed sideroblasts | 3 (3) | 2 (3) | 1 (3) |
| MDS-EB | 25 (22) | 14 (19) | 11 (28) |
| 5q- | 2 (2) | 0 | 2 (5) |
| MDS-U | 6 (5) | 6 (8) | 0 |
| MDS/MPN-U | 6 (5) | 2 (3) | 4 (10) |
| CMML | 16 (14) | 10 (14) | 6 (15) |
| Therapy-related MDS | 20 (18) | 13 (18) | 7 (18) |
| ≥2 cytopenias | 68 (50) | 34 (47) | 22 (55) |
| Transfusion dependence | 59 (52) | 39 (53) | 20 (50) |
| BM blasts percentage | 3 [0-10] | 2 [0-10] | 3 [0-10] |
| Blasts ≥5% | 32 (28) | 21 (29) | 11 (27) |
| Cytogenetic risk (IPSS) | |||
| Good | 69 (61) | 43 (63) | 26 (65) |
| Intermediate | 30 (27) | 17 (23) | 13 (33) |
| Poor | 11 (10) | 10 (14) | 1 (3) |
| IPSS risk group | |||
| Low | 22 (19) | 16 (22) | 6 (15) |
| Intermediate-1 | 91 (81) | 57 (78) | 34 (85) |
| IPSS-R risk group | |||
| Very low | 14 (12) | 10 (14) | 4 (10) |
| Low | 41 (36) | 25 (34) | 16 (40) |
| Intermediate | 34 (30) | 21 (29) | 13 (33) |
| High | 23 (20) | 16 (22) | 7 (18) |
| Very high | 1 (1) | 1 (1) | 0 |
| MDACC LR-MDS score | |||
| Low | 13 (11) | 10 (14) | 3 (8) |
| Intermediate | 52 (46) | 35 (48) | 14 (43) |
| High | 48 (42) | 28 (38) | 20 (40) |
| Prior therapy | |||
| Growth factors | 22 (19) | 12 (16) | 10 (25) |
| Others | 9 (8) | 5 (7) | 4 (10) |
| Time from diagnosis, weeks | 5 [1-271] | 6 [1-216] | 4 [1-271] |
BM, bone marrow; MDACC, MD Anderson Cancer Center; MDS-EB, MDS with excess blasts; MDS-U, MDS, unclassified; MPN-U, myeloproliferative neoplasm, unclassified; RCMD, refractory cytopenia with multilineage dysplasia; RCUD, refractory cytopenia with unilineage dysplasia; WHO, World Health Organization.